# CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct07761572` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07761572](<https://clinicaltrials.gov/study/NCT07761572>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07761572

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 126 participants.

## Technical summary

Registry record NCT07761572. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-15 (anticipated); primary completion 2029-02-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 126 participants (planned count; ClinicalTrials.gov record NCT07761572, source copy `cardio:ctgov-nct07761572-2026-08-12`, retrieved 2026-10-31)
- Planned start: 2026-09-15 (anticipated) (ClinicalTrials.gov record NCT07761572, source copy `cardio:ctgov-nct07761572-2026-08-12`, retrieved 2026-10-31)
- Primary completion: 2029-02-02 (anticipated) (ClinicalTrials.gov record NCT07761572, source copy `cardio:ctgov-nct07761572-2026-08-12`, retrieved 2026-10-31)
- Completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07761572, source copy `cardio:ctgov-nct07761572-2026-08-12`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07761572-2026-08-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
- Acronym: EPIMODE
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): CS1
- Intervention (Drug): Placebo
- Lead sponsor: Cereno Scientific AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 5a711a99f23627ff5e3bb0123d19bbf29ea78261eea594b479ac9c6e386001c4
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
